509 Telbivudine (Ldt) Treatment Effect on Glomerular Filtration Rate (Gfr) in Chronic Hepatitis B (Chb) Patients With Potential Risks of Renal Dysfunction

Gane, E.; Amarapurkar, D.; Chen, Y.-C.; Yan, Zhiqiang; Герасимова, О. А.; Tetova, V.B.; Piratvisuth, Teerha; Chan, Ho-Leung; Deray, Gilbert; Dong, Yi; Trylesinski, Aldo

doi:10.1016/s0168-8278(12)60522-4

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Europe, 20% of the patients with CHB have reduced baseline eGFR of 60 to 89 mL/min/1.73 m 2 . The benefit of telbivudine on eGFR is unique amongst the other nucleos(t)ides . This long‐term improvement of eGFR was not related to viral suppression (in compensated patients) as confirmed by patients with viral suppression under lamivudine treatment who experienced additional eGFR increases only after switch to telbivudine.…”

Section: Discussionmentioning

confidence: 90%

Efficacy and safety of continuous 4‐year telbivudine treatment in patients with chronic hepatitis B

Wang

Thongsawat

Gane

et al. 2012

Journal of Viral Hepatitis

Self Cite

View full text Add to dashboard Cite

In the phase-III GLOBE/015 studies, telbivudine demonstrated superior efficacy vs lamivudine during 2-year treatment in HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB). After completion, 847 patients had an option to continue telbivudine treatment for further 2 years. A total of 596 (70%) of telbivudine-treated patients, who were serum HBV DNA positive or negative and without genotypic resistance to telbivudine at the end of the GLOBE/015 trials, were enrolled into a further 2-year extension study. A group of 502 patients completed 4 years of continuous telbivudine treatment and were included in the telbivudine per-protocol population. Amongst 293 HBeAg-positive patients, 76.2% had undetectable serum HBV DNA and 86.0% had normal serum ALT at the end of 4 years. Notably, the cumulative rate of HBeAg seroconversion was 53.2%. Amongst 209 HBeAg-negative patients, 86.4% had undetectable HBV DNA and 89.6% had normal serum ALT. In patients who had discontinued telbivudine treatment due to HBeAg seroconversion, the HBeAg response was durable in 82% of patients (median 111 weeks of off-treatment follow-up). The cumulative 4-year resistance rate was 10.6% for HBeAg-positive and 10.0% for HBeAg-negative patients. Most adverse events were mild or moderate in severity and transient. Renal function measured by estimated glomerular filtration rate (eGFR) increased by 14.9 mL/min/1.73 m2 (16.6%) from baseline to 4 years (P < 0.0001). In conclusion, in HBeAg-positive and HBeAg-negative CHB patients without resistance after 2 years, two additional years of telbivudine treatment continued to provide effective viral suppression with a favourable safety profile. Moreover, telbivudine achieved 53% of HBeAg seroconversion in HBeAg-positive patients.

show abstract

Section: Discussionmentioning

confidence: 90%

Efficacy and safety of continuous 4‐year telbivudine treatment in patients with chronic hepatitis B

Wang

Thongsawat

Gane

et al. 2012

Journal of Viral Hepatitis

Self Cite

View full text Add to dashboard Cite

show abstract

Advantageous effect of telbivudine on renal function in patients with chronic hepatitis B infection

Yen

Hsu

et al. 2018

Adv in Digestive Medicine

View full text Add to dashboard Cite

In central Taiwan, little is known about the different long‐term effects on renal function of the variant nucleoside analogs for chronic hepatitis B (CHB) patients. We aimed to compare the effects of long‐term use of different nucleoside analogs on renal function at a single medical center. We analyzed patients who fulfilled the criteria of the Bureau of National Health Insurance and received nucleoside analogs between October 1, 2003 and April 30, 2011. Patients were divided into three groups depending on the type of drug administered, which included lamivudine (LAM), entecavir (ETV), and telbivudine (LdT). We excluded CHB patients who received prophylaxis because of chemotherapy and those who underwent bone marrow or liver transplantation. The values of renal function at baseline before treatment and at one year after therapy were analyzed. A total of 307 patients were recruited, including 76 patients who were treated with LAM, 200 patients who were treated with ETV, and 31 patients who were treated with LdT. The initial estimated glomerular filtration rate (eGFR) (T0), as computed by the Modification of Diet in Renal Disease (MDRD) formula and expressed as mL min−1 1.73 m−2, was 86.56 ± 25.30 for LAM, 106.07 ± 36.91 for ETV, and 117.23 ± 42.70 for LdT. The mean change in eGFR (∆eGFR: T12‐T0) at one year after treatment (T12) from baseline (T0) was −3.55 ± 19.13 for LAM, −3.53 ± 22.85 for ETV, and 9.54 ± 29.93 for LdT. For all patients, the ∆eGFR was significantly different between the LdT group and the other two groups (P = 0.006), especially in the subgroups who had eGFR lower than 90 mL min−1 1.73 m−2 (P = 0.001). The type of nucleoside analog was independently associated with ∆eGFR (OR, 4.41; P < 0.001). Renal function improved in CHB patients who received LdT for 1 year compared with those who received LAM or ETV, especially in patients who had eGFR of less than 90 mL min−11.73 m−2.

show abstract

509 Telbivudine (Ldt) Treatment Effect on Glomerular Filtration Rate (Gfr) in Chronic Hepatitis B (Chb) Patients With Potential Risks of Renal Dysfunction

Cited by 2 publications

References 0 publications

Efficacy and safety of continuous 4‐year telbivudine treatment in patients with chronic hepatitis B

Efficacy and safety of continuous 4‐year telbivudine treatment in patients with chronic hepatitis B

Advantageous effect of telbivudine on renal function in patients with chronic hepatitis B infection

Contact Info

Product

Resources

About